JP2009506117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506117A5 JP2009506117A5 JP2008529132A JP2008529132A JP2009506117A5 JP 2009506117 A5 JP2009506117 A5 JP 2009506117A5 JP 2008529132 A JP2008529132 A JP 2008529132A JP 2008529132 A JP2008529132 A JP 2008529132A JP 2009506117 A5 JP2009506117 A5 JP 2009506117A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- related disorder
- disease
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71238705P | 2005-08-31 | 2005-08-31 | |
| US60/712,387 | 2005-08-31 | ||
| PCT/US2006/033278 WO2007027527A2 (en) | 2005-08-31 | 2006-08-25 | Isoindole-imide compounds and compositions comprising and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009506117A JP2009506117A (ja) | 2009-02-12 |
| JP2009506117A5 true JP2009506117A5 (enExample) | 2009-10-08 |
| JP5578785B2 JP5578785B2 (ja) | 2014-08-27 |
Family
ID=37758733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529132A Active JP5578785B2 (ja) | 2005-08-31 | 2006-08-25 | イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20070049618A1 (enExample) |
| EP (1) | EP1919892B1 (enExample) |
| JP (1) | JP5578785B2 (enExample) |
| KR (1) | KR20080042158A (enExample) |
| CN (1) | CN101291924A (enExample) |
| AR (1) | AR055150A1 (enExample) |
| AU (1) | AU2006285144A1 (enExample) |
| BR (1) | BRPI0614995A2 (enExample) |
| CA (3) | CA2822094C (enExample) |
| CR (1) | CR9772A (enExample) |
| DO (1) | DOP2006000193A (enExample) |
| EC (1) | ECSP088332A (enExample) |
| ES (1) | ES2434946T3 (enExample) |
| GT (1) | GT200600398A (enExample) |
| IL (1) | IL189795A0 (enExample) |
| MX (1) | MX2008002765A (enExample) |
| NO (1) | NO20081554L (enExample) |
| PA (1) | PA8693101A1 (enExample) |
| PE (1) | PE20070541A1 (enExample) |
| RU (1) | RU2008112221A (enExample) |
| TW (1) | TW200745078A (enExample) |
| UA (1) | UA91560C2 (enExample) |
| WO (1) | WO2007027527A2 (enExample) |
| ZA (1) | ZA200802490B (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2579291C (en) * | 2004-09-03 | 2011-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| SI2380887T1 (sl) | 2005-06-30 | 2013-12-31 | Celgene Corporation | Postopki priprave spojin 4-amino-2-/2,6-dioksopiperidin-3-il)izoindolin -1,3-diona |
| ES2434946T3 (es) * | 2005-08-31 | 2013-12-18 | Celgene Corporation | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| JP2011505808A (ja) * | 2007-12-07 | 2011-03-03 | セルジーン コーポレイション | 非ホジキンリンパ腫の治療の間における、免疫調節化合物に対する細胞の感受性を予測するためのバイオマーカー |
| CA2710196A1 (en) * | 2007-12-20 | 2009-07-09 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| US20090232796A1 (en) * | 2008-02-20 | 2009-09-17 | Corral Laura G | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| SG195613A1 (en) * | 2008-10-29 | 2013-12-30 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer |
| CA2756594C (en) | 2009-03-25 | 2021-03-23 | Anthrogenesis Corporation | Treatment of viral infection using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
| WO2010137547A1 (ja) | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| MX337566B (es) | 2010-01-05 | 2016-03-10 | Celgene Corp | Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. |
| SI3202460T1 (sl) | 2010-02-11 | 2019-10-30 | Celgene Corp | Arilmetoksi izoindolin derivati in sestavki, ki jih obsegajo in metode za uporabo le-teh |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| EP2699909A1 (en) | 2011-04-18 | 2014-02-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| CA2877736C (en) | 2012-06-29 | 2021-12-07 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| TW201526897A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| CN103396397A (zh) * | 2013-08-14 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 来那度胺衍生物及其作为药物的用途 |
| WO2015030189A1 (ja) * | 2013-08-29 | 2015-03-05 | 京都薬品工業株式会社 | 新規芳香族化合物およびその用途 |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6778114B2 (ja) * | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| WO2016065980A1 (zh) * | 2014-10-30 | 2016-05-06 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
| HK1247204A1 (zh) | 2015-01-20 | 2018-09-21 | Arvinas Operations, Inc. | 用於雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3317287B1 (en) | 2015-07-02 | 2019-07-31 | GlaxoSmithKline Intellectual Property Development Limited | Inhibitors of indoleamine 2,3-dioxygenase |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| JP7001614B2 (ja) * | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | リガンド依存性の標的タンパク質分解のための単官能性中間体 |
| KR20250044800A (ko) | 2016-10-11 | 2025-04-01 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적 분해용 화합물 및 방법 |
| JP7286539B2 (ja) | 2016-11-01 | 2023-06-05 | アルビナス・オペレーションズ・インコーポレイテッド | タウタンパク質標的化ｐｒｏｔａｃ、および関連使用方法 |
| DK3689868T3 (da) | 2016-12-01 | 2024-01-02 | Arvinas Operations Inc | Tetrahydronaphthalen- og tetrahydroisoquinolinderivater som østrogenreceptordegraderende midler |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| AU2017382436C1 (en) | 2016-12-23 | 2021-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| CN112041319B (zh) | 2018-01-26 | 2024-05-14 | 利康化学与制药工业有限公司 | 三唑、咪唑和吡咯稠合的哌嗪衍生物及其作为mGlu5受体的调节剂的应用 |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| EP3755718A1 (en) | 2018-02-21 | 2020-12-30 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| MY206796A (en) | 2018-04-23 | 2025-01-08 | Celgene Corp | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| KR20250020690A (ko) * | 2018-06-29 | 2025-02-11 | 다나-파버 캔서 인스티튜트 인크. | 세레블론(crbn)에 대한 리간드 |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| WO2020064002A1 (zh) | 2018-09-30 | 2020-04-02 | 中国科学院上海药物研究所 | 异吲哚啉类化合物、其制备方法、药物组合物及用途 |
| WO2020102195A1 (en) | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| CA3122317C (en) | 2018-12-06 | 2023-10-03 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound |
| CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
| BR112021022758A2 (pt) * | 2019-05-31 | 2022-03-22 | Celgene Corp | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN119019369A (zh) | 2019-10-17 | 2024-11-26 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| CN118638043A (zh) | 2019-12-19 | 2024-09-13 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| US12410171B2 (en) | 2020-02-26 | 2025-09-09 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| EP4146642A1 (en) | 2020-05-09 | 2023-03-15 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| CN114057592B (zh) * | 2020-08-05 | 2023-08-22 | 沈阳化工研究院有限公司 | 一种制备4-氨基甲基苯甲酸的方法 |
| JP2023539663A (ja) | 2020-08-28 | 2023-09-15 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| CN116390916A (zh) | 2020-09-14 | 2023-07-04 | 阿尔维纳斯运营股份有限公司 | 用于靶向降解雌激素受体的化合物的结晶形式 |
| PE20230847A1 (es) | 2020-09-23 | 2023-05-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon |
| CN114591192B (zh) * | 2020-12-04 | 2024-06-21 | 江西仰立新材料有限公司 | 一种n-环丙甲基苯胺类化合物的制备方法 |
| WO2022148459A1 (zh) * | 2021-01-11 | 2022-07-14 | 和径医药科技（上海）有限公司 | 一类新型Smad3蛋白降解剂及其应用 |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023287726A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of cancer using botulinum toxin and nitrous oxide |
| US20250122166A1 (en) * | 2021-11-03 | 2025-04-17 | St. Jude Children's Research Hospital, Inc. | Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)methyl)benzamide analogs as modulators of cereblon protein |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| AR130961A1 (es) | 2022-11-04 | 2025-02-05 | Bristol Myers Squibb Co | Compuestos y su uso para el tratamiento de hemoglobinopatías |
| WO2024159164A2 (en) | 2023-01-26 | 2024-08-02 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| CN116473975A (zh) * | 2023-04-11 | 2023-07-25 | 东南大学 | 奥沙普秦和异烟酰胺或吡嗪酰胺低共熔物、药物组合物及其制备方法 |
| WO2024222918A1 (zh) * | 2023-04-28 | 2024-10-31 | 中国药科大学 | 一种苯并六元杂环类gspt1蛋白降解剂及其应用 |
| KR20250054737A (ko) * | 2023-10-16 | 2025-04-23 | 주식회사 아스트로젠 | 신규한 분자 접착제의 용도 |
| CN120289981B (zh) * | 2025-06-13 | 2025-08-29 | 兴邦新材料(山东)有限公司 | 高尺寸稳定性的tpu材料及其制备方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB508048A (en) | 1937-12-24 | 1939-06-26 | Marconi Wireless Telegraph Co | Improvements in or relating to aerial systems |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
| TR200101502T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| ES2434946T3 (es) | 2005-08-31 | 2013-12-18 | Celgene Corporation | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo |
| WO2010003001A1 (en) | 2008-07-03 | 2010-01-07 | Dow Global Technologies Inc. | Improved method of operating a compression ignition internal combustion engine |
| KR20160100584A (ko) | 2015-02-16 | 2016-08-24 | 에스케이하이닉스 주식회사 | 반도체 메모리 장치 및 그의 테스트 방법 |
-
2006
- 2006-08-25 ES ES06813767T patent/ES2434946T3/es active Active
- 2006-08-25 CA CA2822094A patent/CA2822094C/en active Active
- 2006-08-25 MX MX2008002765A patent/MX2008002765A/es not_active Application Discontinuation
- 2006-08-25 KR KR1020087007833A patent/KR20080042158A/ko not_active Withdrawn
- 2006-08-25 JP JP2008529132A patent/JP5578785B2/ja active Active
- 2006-08-25 CA CA2620085A patent/CA2620085C/en active Active
- 2006-08-25 AU AU2006285144A patent/AU2006285144A1/en not_active Abandoned
- 2006-08-25 RU RU2008112221/04A patent/RU2008112221A/ru not_active Application Discontinuation
- 2006-08-25 EP EP06813767.8A patent/EP1919892B1/en active Active
- 2006-08-25 BR BRPI0614995-2A patent/BRPI0614995A2/pt not_active IP Right Cessation
- 2006-08-25 CA CA2899923A patent/CA2899923A1/en not_active Abandoned
- 2006-08-25 WO PCT/US2006/033278 patent/WO2007027527A2/en not_active Ceased
- 2006-08-25 ZA ZA200802490A patent/ZA200802490B/xx unknown
- 2006-08-25 UA UAA200803946A patent/UA91560C2/ru unknown
- 2006-08-25 CN CNA2006800393786A patent/CN101291924A/zh active Pending
- 2006-08-30 PA PA20068693101A patent/PA8693101A1/es unknown
- 2006-08-30 TW TW095132015A patent/TW200745078A/zh unknown
- 2006-08-30 US US11/513,563 patent/US20070049618A1/en not_active Abandoned
- 2006-08-31 DO DO2006000193A patent/DOP2006000193A/es unknown
- 2006-08-31 AR ARP060103821A patent/AR055150A1/es unknown
- 2006-08-31 PE PE2006001061A patent/PE20070541A1/es not_active Application Discontinuation
- 2006-08-31 GT GT200600398A patent/GT200600398A/es unknown
-
2008
- 2008-02-26 IL IL189795A patent/IL189795A0/en unknown
- 2008-02-28 CR CR9772A patent/CR9772A/es not_active Application Discontinuation
- 2008-03-28 NO NO20081554A patent/NO20081554L/no not_active Application Discontinuation
- 2008-03-31 EC EC2008008332A patent/ECSP088332A/es unknown
-
2011
- 2011-02-17 US US13/030,075 patent/US8481568B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009506117A5 (enExample) | ||
| JP2010504973A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2008528514A5 (enExample) | ||
| WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
| JP2018021046A5 (enExample) | ||
| WO2008020040A3 (en) | 2,5-dihydroxybenzene compounds for the treatment of fibrosis | |
| WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
| NZ599199A (en) | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same | |
| MX356032B (es) | Compuestos indola y métodos para tratar el dolor visceral. | |
| GB0520751D0 (en) | Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease | |
| BRPI0807749A2 (pt) | Composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos. | |
| JP2007514005A5 (enExample) | ||
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| WO2007128802A3 (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
| WO2004074246A3 (en) | Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | |
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| BRPI0719880A2 (pt) | Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma. | |
| BRPI0816255A2 (pt) | Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável | |
| WO2007048801A3 (en) | Sexual desire enhancing medicaments comprising benzimidazolone derivatives | |
| WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
| JP2012502915A5 (enExample) | ||
| PL2196206T3 (pl) | Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną | |
| JP2009541409A5 (enExample) | ||
| CL2007002133A1 (es) | Compuestos derivados de cromenos o tiocromenos carboxamidas, ligandos dopaminergicos d3; procedimento de preparacion; composicion farmaceutica; y uso para el tratamiento de una enfermedad o de un trastorno neurologico o psiquiatrico tal como enfermed |